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Abstract
The global epidemic of obesity (globesity) and related cardiometabolic and cancer 
diseases has focused attention on adipose tissue biology and the role played by adi-
pose-secreted bioactive molecules (adipokines, neurotrophic factors, fatty acids, pros-
taglandins, steroid hormones, vitamin D3, NO, H2S) in the regulation of a wide array of 
physiological and pathological processes. Until recently, physicians have looked upon 
obesity as an accumulation of external adipose tissue (subcutaneous and abdominal). 
This was routinely evaluated by anthropometric measurements including body mass 
index and waist, hip and, recently, neck circumference. However, recent data using 
non-invasive imaging methods (echography, computed tomography, magnetic reso-
nance imaging, and positron emission tomography), reveal a novel picture of adipo-
topography (fat mapping). Together with secretory functions, such a topography has 
been conceptualized as two major subfields of adipobiology, adipoendocrinology and 
adipoparacrinology. Here we introduce periprostatic adipose tissue as an example of 
adipoparacrinology of prostate cancer; its implication in the therapy is also outlined.
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Introduction
Recently, the prevalence of obesity 
and related cardiometabolic and can-
cer diseases is increasing dramatically 
and globally. Arguably, more has been 
learned about the molecular control 
of food intake, particularly the role 
played by adipose tissue in the patho-
genesis of these diseases, studying the 
structure and function of both white 
adipose tissue (1-15) and brown adi-
pose tissue (“thermogenic tissue”, a 
term suggested by Caroline Pond, per-
sonal communication). 
Human adipose tissue is parti-
tioned into two large depots (sub-
cutaneous and visceral), and many 
small depots associated with internal 
organs, e.g. heart, blood vessels, major 
lymph nodes, pancreas, kidneys, pros-
tate gland and ovaries. Since the dis-
covery of leptin in 1994, the adipose 
tissue has been perceived not merely 
as a lipid store, but as a secretory – 
endocrine and paracrine – organ. 
Evidence for paracrine interactions 
between adipose tissue and other tis-
sues was presented in the 1990s by 
ADIPOPARACRINOLOGY: PERIPROSTATIC ADIPOSE TISSUE  
AS AN EXAMPLE
DANCe ROUND
We dance round in a ring and suppose,
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Pond and Mattacks (1), but the secretory function of adipose 
tissue was not conceptualized until the early 2000s when two 
major subfields of adipobiology - adipoendocrinology and adi-
poparacrinology - have emerged (2,3, reviewed in 7,12-14).      
Inflammation, immunity, endothelial dysfunction, insulin 
resistance, vascular tone, hemostasis, reproduction, cell growth, 
memory/learning, and vitamin D3 and bone metabolism (see 
Trayhurn et al, Bełtowski, Kanazawa, and Gualillo, this volume 
of Adipobiology) have been implicated in the effects of adiposity 
on human health and disease. 
Adipoparacrinology of prostate cancer
Obesity is associated with larger size of prostate cancer and 
higher Gleason scores. However, the mechanisms by which obe-
sity promotes prostate cancer remain unknown. We hypothesize 
that the prostate may be the target of various pro-cancerogenic 
adipokines (8-11), at paracrine level focusing on the potential 
role of periprostatic adipose tissue. This tissue was neglected 
until recently when few publications had been released (16-18). 
In one of these latter studies (16), periprostatic adipose tissue 
has been harvested from patients undergoing radical prostatec-
tomy, and  interleukin-6 in periprostatic adipose tissue condi-
tioned medium was approximately 375 times greater than that 
in patient matched serum; this correlated with higher patho-
logical Gleason score in 45 patients. These findings suggest that 
periprostatic adipose tissue may have a role in modulating pros-
tate cancer aggressiveness by serving as a source of pro-cancer-
ogenic adipokines. Likewise, the presence of periprostatic adi-
pose tissue measured  by computed tomography correlates with 
prostate cancer aggressiveness (18). 
Adipopharmacology of prostate cancer
To date, no effective therapeutic treatment prevents prostate 
cancer progression to more advanced and invasive disease 
forms. The prostate is an abundant source of nerve growth fac-
tor (NGF) that is secreted by malignant epithelial cells and uti-
lized as an important autocrine factor for growth and metasta-
sis. Recently, the possible “oncotrophic” role of this “classical” 
neurotrophin, which is also produced by adipose tissue (6 and 
references therein), in the pathogenesis of prostate cancer has 
been reported (19-23). In our ongoing study, we are collecting 
samples of periprostatic and anterior perirectal adipose tissue 
from prostate cancer patients undergoing radical prostatectomy, 
aimed at studying the immunohistochemical expression of NGF 
receptors, p75NTR and TrkA, and of BDNF receptor, TrkB. Note-
worthy, CEP-701 (Lestaurtinib), a pan tyrosine kinase receptor 
(Trk)  inhibitor that causes cell death in prostate cancer models 
(24), is in clinical trials (25,26). In the same vein, tamoxifen, a 
drug traditionally applied in breast cancer therapy (27), might 
also be considered in the therapy of prostate cancer. Further, 
adiponectin receptor agonists (28,29) and/or leptin receptor 
antagonists (30) may also be of therapeutic value. Last but not 
least, new adipokines, semaphorins, and their receptors, neuro-
pilins and plexins (31), were implicated in the pathogenesis of 
prostate cancer (32).
Coda
Many routes may lead to the transition from healthy to diseased 
phenotype. However, there are not so many routes to travel the 
opposite direction, that is, to treat obesity and related diseases, 
and thus extend human life expectancy. The principle questions 
thus remain: which are the pathogenic routes, and how would be 
they counteracted for therapeutic purposes?  
Here, we have Danced Round the dysfunctional periprostatic 
adipose tissue paracrine secretion of adipokines as implicated in 
the pathogenesis of prostate cancer and, possibly, benign pro-
static hyperplasia. Mechanistically, each step of the intracellu-
lar secretory pathway of these adipokines might be a potential 
target for drug development. Although a significant amount of 
work is still required to uncover the multiplex biology of both 
adipose secretion and prostate cancer, the present Dance Round 
proposes that a detailed molecular understanding of paracrine 
secretion may open new avenues for discovering drugs for pros-
tate cancer as well as other, adipose tissue-related diseases (Ta-
ble 1). Thus, the present challenge is to cul tivate an adipocentric 
thinking about how we can make the adipose tissue secretion 
work for the benefit of human’s health.
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